EDNRA and cancer: ET-1R blockade by macitentan, a dual ETAR/ETBR-antagonist, FDA-approved for the treatment of pulmonary arterial hypertension3, sensitizes tumor cells to different cytotoxic and targeted agents in various preclinical tumor models, including ovarian, colorectal cancer, glioblastoma, multiple myeloma, breast, and lung brain metastasis4,36–43, and may represent an effective therapeutic option for cancer patients.